DEF: Establishment Labs Holdings Inc. Announces Details for 2025 Annual Meeting of Shareholders

Establishment Labs Holdings Inc. will hold its 2025 Annual Meeting of Shareholders virtually on May 23, 2025, to vote on director elections, executive compensation, and the ratification of the company's accounting firm.

Summary

• Establishment Labs Holdings Inc. will hold its 2025 Annual Meeting of Shareholders on May 23, 2025, at 1:00 pm Eastern Time, via live audio webcast.
• Shareholders of record as of April 2, 2025, are entitled to vote at the meeting.
• The meeting will address the election of five director nominees, an advisory vote on executive compensation, and the ratification of CBIZ, Inc. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board recommends voting FOR the election of the director nominees, FOR the executive compensation, and FOR the ratification of CBIZ, Inc.
• The company's revenue for 2024 was $166.0 million, a slight increase from $165.2 million in 2023.
• Net losses for 2024 were $84.6 million, compared to $78.5 million in 2023.
• The cash balance as of December 31, 2024, was $90.3 million.
• The Board consists of six directors, four of whom are independent.
• The Board is in the process of interviewing candidates to fill the vacant seat.
• The Board has nominated Juan Jos Chacn Quirs, Ann Custin, Nicholas Lewin, Edward Schutter and Bryan Slotkin as director nominees for election at the Annual Meeting for a term expiring at the annual meeting of shareholders to be held in 2026.
• The company's executive compensation program includes base salaries, annual incentive compensation opportunities, and long-term incentive awards.
• The Compensation Committee believes that the executive compensation program objective is to reward our executives for successfully creating long-term shareholder value.
• The Compensation Committee utilizes a mix of stock options and restricted stock unit awards in order to link the NEOs interests to those of our shareholders.
• The Compensation Committee has also created an annual incentive plan design that utilizes a carefully calibrated set of performance objectives focused on revenue growth, operating expenses, product development, the expansion of our geographic footprint and other strategic objectives that we believe will lead to long-term value creation.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily providing factual information about the upcoming annual meeting and corporate governance matters. The increase in net losses is a negative point, but the overall sentiment is balanced.

Positives

• The company's revenue saw a slight increase in 2024, reaching $166.0 million.
• The company maintains a solid cash balance of $90.3 million as of December 31, 2024.
• The Board is actively engaged in corporate governance, regularly reviewing practices and ensuring compliance.
• The company has a share ownership policy for non-employee directors to align their interests with shareholders.
• The company has a clawback policy for executive compensation in case of accounting restatements.
• The company provides severance protections to executive officers under their employment agreements.

Negatives

• Net losses increased in 2024 to $84.6 million, compared to $78.5 million in 2023.
• The company's executive compensation program is complex and may not be easily understood by all shareholders.
• The company's CEO pay ratio is 86 to 1, which may be a concern for some shareholders.
• The company's total shareholder return has been volatile in recent years.

Risks

• The company faces risks related to its compensation policies and practices, which could incentivize employees to take excessive risks.
• The company's reliance on a few key executives could pose a risk if those executives were to leave the company.
• The company's business is subject to regulatory risks, including the risk of product recalls or other regulatory actions.
• The company's business is subject to competitive risks, including the risk of new products or technologies from competitors.

Future Outlook

The document does not contain specific forward-looking statements or guidance beyond the details of the upcoming annual meeting.

Management Comments

• We appreciate your continued support of Establishment Labs.
• Our Board believes that sound corporate governance is fundamental to the overall success of Establishment Labs and believes that it has adopted corporate governance practices that are aligned with the interests of our shareholders and our corporate business strategy.

Industry Context

The document provides standard information related to the company's annual meeting and corporate governance. It does not offer specific insights into broader industry trends or competitive dynamics beyond the peer group used for compensation benchmarking.

Comparison to Industry Standards

• The document mentions a peer group of companies used for executive compensation benchmarking, including Artivion, Inspire Medical Systems, AtriCure, OrthoPediatrics Corp., Atrion Corporation, Paragon 28, AxoGen, Revance Therapeutics, Axonics, Sientra, Inc., BioLife Solutions, Silk Road Medical, Cutera, STAAR Surgical Company, Evolus, The Beauty Health Company, Inari Medical, and Treace Medical Concepts.
• The company aims to position its total revenues, market capitalization, and operating income at approximately the median relative to its peer group companies.
• The Compensation Committee's philosophy is that each executive's targeted total direct compensation should be at or below the 50th percentile of the targeted total direct compensation provided by its peer companies to similarly situated executives.

Management Changes

Related Party Transactions

• The Company recorded revenue of $1.1 million for product sales to Herramientas Medicas, S.A., a distribution company owned by a family member of Mr. Chacn Quirs.
• The Company paid Dr. Chacn Quirs approximately $0.2 million for services rendered.

Stakeholder Impact

• Shareholders are asked to vote on key proposals, including director elections and executive compensation.
• Employees are affected by the company's compensation policies and benefit plans.
• The company's performance and governance practices impact its reputation and relationships with customers and suppliers.

Next Steps

• Shareholders are urged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Shareholders on May 23, 2025.
• The Board will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Shareholders, Board of Directors, Executive Compensation, Director Nominees, CBIZ, Accounting Firm, Corporate Governance, Establishment Labs